The Northern-European Initiative on Colorectal Cancer

Overview

Colorectal cancer (CRC) is a major burden in western countries. The disease develops from precursor lesions during a long time-interval. Colonoscopy can detect and remove CRC precursor lesions and may thus be effective for CRC prevention. Many national and international health organisations demand evidence from randomised trials to reduce incidence or mortality of the target disease before advocating population-wide cancer screening. However, while colonoscopy screening for the prevention of colorectal cancer is established in the United States and several European countries, no randomised trials exist to quantify the possible benefit of colonoscopy screening. NordICC is a randomised trial investigating the effect of colonoscopy on CRC incidence and mortality. NordICC is a multicentre, randomised trial in Nordic countries, the Netherlands and Poland. A minimum of 66 000 individuals, age 55-64 years, are drawn randomly from the population registries in the participating countries. 22 000 are invited for once-only colonoscopy (2:1 randomisation). Expected work-load with 50% compliance will be 11,000 colonoscopies. At the screening examination, all detected lesions are biopsied and removed whenever possible. The remaining 44 000 individuals (control group) are not offered any screening examination (care as usual).The primary study aims are CRC incidence and CRC mortality after 15 years of follow-up, with an interim analysis after 10 years of follow-up. In an intention-to-treat approach, a risk reduction of CRC mortality of 25% in the colonoscopy screening group compared to the control group is expected after 10 years follow-up, estimating 50% compliance in the screening group.

Full Title of Study: “NordICC The Northern-European Initiative on Colorectal Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2026

Interventions

  • Procedure: Colonoscopy
    • Once-only colonoscopy screening

Arms, Groups and Cohorts

  • Experimental: Colonoscopy screening
    • One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
  • No Intervention: Control
    • The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs. All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable.

Clinical Trial Outcome Measures

Primary Measures

  • Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence
    • Time Frame: 15 years after screening (interim analysis after 10 years)

Secondary Measures

  • CRC mortality and CRC incidence of screening attendees compared to the control group and non-attendees
    • Time Frame: 15 years after screening (interim analysis after 10 years)
  • Mortality from all causes
    • Time Frame: 15 years after screening (interim analysis after 10 years)

Participating in This Clinical Trial

Inclusion Criteria

  • This study is a population-based randomised controlled trial, with randomisation of individuals age 55-64 years living in the screening areas directly from the Population Registries to either screening group or control group. Eligible persons with the same home address will be randomised to the same group (household randomisation). Exclusion Criteria:

  • Individuals with previous colorectal surgery (resections, enterostomies) – Individuals in need of long-lasting attention and nursing services (somatic or psychosocial, mental retardation). – On-going cytotoxic treatment or radiotherapy for malignant disease – Severe chronic (longer than trial duration) cardiac (NYHA III-IV)or lung disease – Lifelong anticoagulant therapy with Warfarin – A coronary event requiring hospitalization during the last 3 months – A cerebrovascular event during the last 3 months – Resident abroad – Return of unopened letter of invitation and/or reminder (address unknown) – Message from neighbour/family/post office on death of screenee (not updated in Population Registry)

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Oslo University Hospital
  • Collaborator
    • Maria Sklodowska-Curie National Research Institute of Oncology
  • Provider of Information About this Clinical Study
    • Principal Investigator: Michael Bretthauer, Professor – University of Oslo
  • Overall Official(s)
    • Hans-Olov Adami, MD PhD, Study Director, Harvard School of Public Health, Boston, USA
    • Michael Bretthauer, MD PhD, Principal Investigator, Oslo University Hospital
    • Michal Filip Kaminski, MD PhD, Principal Investigator, Marie Cure Sklodowska Cancer Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.